From Little Akorn Grows a Great Stock

NEW YORK (TheStreet) -- This is the year of the small and mid-cap domestic stock, such as Akorn (AKRX). For many smart investors, it is the year that traditional asset allocation among stocks, bonds and gold has finally outlived it usefulness.

Data from Best Stocks Now App

I am not a believer in the traditional asset allocation models that are built on the Model Portfolio Theory that says investors need so much money in stocks -- often for growth -- and so much in bonds - often for income. And often so much in gold for security.

There are lots of places to get income besides bonds. Instead, I move around among the various asset classes as world and economic conditions dictate.

When it became obvious about 18 months ago that interest rates had nowhere to go but up, and the Federal Reserve had no other choice but to tighten at some point, I got out of the way of the freight train that was headed right for the market.

I got out of bonds, just in time to avoid the beating that bonds took this year: The U.S. long bond, as seen by the iShares Barclays 20+ Yr Treasury Bond (TLT) exchange-traded fund, is now down 14.7% for the year to date.

I have also not had any exposure to the emerging markets as they have been at the bottom of my asset class rankings since the beginning of the year. That too has helped my performance greatly in 2013 as the emerging markets as a whole are down about 9% year-to-date. Contrast this with the 24% return of the U.S. S&P 500 index.

Gold has also been a bad place to be in 2013 as it is now down over 23% year-to-date. So much for asset allocation into gold.

Instead, I have been heavily focused in small and mid-cap domestic stocks which have led the market all year long. The S&P 500 small-cap index is up a whopping 32.8% year to date.

Being in the right sectors of the market is a great place to start selecting investments. 2013 has been a year that has greatly favored pharmaceutical, biotech, and technology stocks. Of course, this is where a lot of small and mid-cap stocks reside.

If you liked this article you might like

Teva, Mylan Seen to Stay on M&A Sidelines

Merger Buzz Drives Akorn to Top of Health Chart in April

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

European Stocks High on French Perfume and Trump Bump

Analysts' Actions -- Amazon, C.R. Bard, CyrusOne, Dow and More